Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
For years many of us have lamented the butchering that Dr. Steven Nissen gave to the TZDs. Part of this came from the extra cardiovascular studies that every manufacturer had to do on new diabetes drugs that came to market. Many of you thought that those studies were useless and only added time and extra expenses to the approval process. But we might actually have to thank the good doctor for his direction, as these studies are now showing the positive cardiovascular effects of drugs like Cycloset, Januvia, Invokana and the like.
This month we are focusing on the cardiovascular benefits of the DPP-4i’s and why they are a great choice either alone or in combination with other medications, such as metformin.
Dave Joffe
Editor-in-chief
Can DPP-4 inhibitors and GLP-1 analogues cause bile duct and gallbladder complications?
Alogliptin is efficient and safe in the management of type 2 diabetes even in patients who have cardiovascular disease as a comorbidity.
Large observational study using real-world data finds no increased risk for hospitalized heart failure (hHF) among patients who initiated use of DPP-4 inhibitors, compared to other antihyperglycemics.
Reduce the dose of sulphonylureas when adding DPP-4 inhibitor treatment in patients with type 2 diabetes, study warns.